RNUGF has been the topic of a number of other reports. Zacks Investment Research downgraded ReNeuron Group from a buy rating to a hold rating in a research note on Tuesday, July 23rd. Maxim Group reaffirmed a buy rating and issued a $6.00 price target on shares of ReNeuron Group in a research report on Thursday, September 12th.
Shares of RNUGF stock opened at $1.55 on Tuesday. The stock’s 50 day simple moving average is $2.59 and its 200 day simple moving average is $2.90. ReNeuron Group has a twelve month low of $0.57 and a twelve month high of $4.43.
ReNeuron Group plc develops and sells cell-based therapies in the United Kingdom. The company's lead therapeutic candidate is CTX stem cell therapy, which has been completed Phase II clinical trial for the treatment of patients living with chronic disability following stroke, as well as that has been completed Phase I clinical trial to treat limb ischaemia.
See Also: Overbought
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for ReNeuron Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ReNeuron Group and related companies with MarketBeat.com's FREE daily email newsletter.